Immunovia
Immunovia AB is a diagnostic company focused on increasing survival rates for patients with pancreatic cancer through early detection. The company specializes in developing and commercializing blood-based tests that detect proteins and antibodies indicative of pancreatic cancer in high-risk individuals. Immunovia collaborates with healthcare providers, leading experts, and patient advocacy groups to make its tests widely available. The company's shares are listed on Nasdaq Stockholm, and it is headquartered in Lund, Sweden.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueBlood-based tests for detecting pancreatic cancer
Services providing clinical data and testing results
Collaborations for commercialization and distribution
Customers
Immunovia's primary customers are healthcare providers and medical centers that focus on high-risk pancreatic cancer surveillance. These customers integrate Immunovia's PancreaSure test into their surveillance protocols to enhance early detection capabilities. The company also targets strategic partners in the diagnostics industry to expand its commercial reach and accelerate market penetration. Additionally, Immunovia engages with patient advocacy groups to raise awareness and promote the adoption of its testing solutions.
Purchase PancreaSure for early detection in high-risk patients
Integrate tests into surveillance protocols
Collaborate for commercialization and distribution
Support awareness and adoption of testing solutions
Strategy
Immunovia's strategic priorities include the commercialization of its PancreaSure test, securing strategic partnerships, and achieving reimbursement for its tests. The company focuses on targeted launches in the US market, leveraging relationships with top pancreatic cancer specialists to drive adoption. Immunovia is actively seeking a strategic partner to expand its commercial reach and accelerate market penetration. The company is also conducting additional clinical studies to secure reimbursement and enhance its competitive position.
To increase market penetration and revenue
To expand commercial reach and reduce costs
To enhance test adoption and financial sustainability
Geography
Immunovia is headquartered in Lund, Sweden, and its primary market is the United States, which is the largest market for pancreatic cancer detection. The company estimates that 1.8 million individuals in the USA are at high risk for pancreatic cancer and could benefit from annual surveillance testing. Immunovia's strategic focus includes expanding its presence in the US through partnerships and collaborations with major medical centers. The company also explores opportunities for global distribution through strategic partners outside the US.
Risks
Immunovia faces several operational and financial risks, including the development and validation of new tests, dependence on collaboration partners, and market acceptance challenges. The company is also exposed to currency risks due to its international operations, primarily related to USD and EUR fluctuations. Additionally, there are risks related to securing reimbursement and competition in the diagnostics industry. Liquidity risk is managed through careful cash flow planning and securing necessary funding.
- Development and validation of new testsImpact: HighLikelihood: High
Critical for product success and market entry
- Market acceptance and reimbursementImpact: HighLikelihood: High
Essential for revenue generation and growth
- Currency risksImpact: MediumLikelihood: Low
Exposure to USD and EUR affects financial results
Accounting
Judgemental itemsAffects timing and accuracy of reported revenue
Impact: high
Impacts financial liabilities and cash flow
Impact: medium
Similar listed companies
Publicly listed companies with a comparable business focus.
CellaVision
CEVI · Health Care
CellaVision is a global medical technology company specializing in the development and sale of advanced solutions for the routine analysis of blood and other body fluids.
Cantargia
CANTA · Health Care
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases.
Immatics N.V.
IMTX · Biological Products, (No Diagnostic Substances)
IQVIA Holdings, Inc
IQV · Services-Commercial Physical & Biological Research
Immunovant, Inc.
IMVT · Biological Products, (No Diagnostic Substances)
TuHURA Biosciences, Inc.
HURA · Pharmaceutical Preparations
TuHURA Biosciences, Inc./NV is a Nevada-based clinical-stage immuno-oncology company focused on developing therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies.
Last updated: 24/09/2026